Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia

scientific article published on 01 January 1999

Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia is …
instance of (P31):
scholarly articleQ13442814
meta-analysisQ815382

External links are
P698PubMed publication ID10603070

P50authorSiegfried KasperQ2283474
P2093author name stringH J Möller
J M Azorin
A Hale
P407language of work or nameEnglishQ1860
P921main subjectschizophreniaQ41112
risperidoneQ412443
P304page(s)II1-II14
P577publication date1999-01-01
P1433published inEuropean Archives of Psychiatry and Clinical NeuroscienceQ661388
P1476titleBenefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia
P478volume249 Suppl 2

Reverse relations

cites work (P2860)
Q30482602Behavioral and neurobiological changes in C57BL/6 mouse exposed to cuprizone: effects of antipsychotics.
Q57738646Früherkennung und Frühintervention der Schizophrenie
Q51822628Optimized voxel brain morphometry: association between brain volumes and the response to atypical antipsychotics.
Q36418019Sertindole : a review of its use in schizophrenia
Q34658561The European post-marketing observational sertindole study: an investigation of the safety of antipsychotic drug treatment

Search more.